Why the study?
Does atorvastatin reduce myocardial fibrosis in db/db mice with diabetic cardiomyopathy?
Does atorvastatin reduce myocardial fibrosis in db/db mice with diabetic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
This editorial highlights preclinical evidence suggesting that atorvastatin may ameliorate diabetic cardiomyopathy by reducing myocardial fibrosis through antioxidant and anti-inflammatory mechanisms.
In this editorial, we commented on the article published in the recent issue of the World Journal of Diabetes . Diabetic cardiomyopathy (DCM) is characterized by myocardial fibrosis, ventricular hypertrophy and diastolic dysfunction in diabetic patients, which can cause heart failure and threaten the life of patients. The pathogenesis of DCM has not been fully clarified, and it may involve oxidative stress, inflammatory stimulation, apoptosis, and autophagy. There is lack of effective therapies for DCM in the clinical practice. Statins have been widely used in the clinical practice for years mainly to reduce cholesterol and stabilize arterial plaques, and exhibit definite cardiovascular protective effects. Studies have shown that statins also have anti-inflammatory and antioxidant effects. We were particularly concerned about the recent findings that atorvastatin alleviated myocardial fibrosis in db/db mice by regulating the antioxidant stress and anti-inflammatory effects of macrophage polarization on diabetic myocardium, and thereby improving DCM.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: